

PCT

WORLD INTELLEC  
In



WO 9603656A1

INTERNATIONAL APPLICATION PUBLISHED

(51) International Patent Classification <sup>6</sup> :

G01N 33/68, 33/92

A--

(43) International Publication Date: 8 February 1996 (08.02.96)

(21) International Application Number: PCT/EP95/02827

(22) International Filing Date: 13 July 1995 (13.07.95)

(30) Priority Data:  
9415073.7 27 July 1994 (27.07.94) GB

(71) Applicants (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW [GB/GB]; University Avenue, Glasgow G12 8QQ (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ROBERTS, Gareth, Wyn [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). GRAHAM, David, Ian [GB/GB]; The University Court of the University of Glasgow, University Avenue, Glasgow G12 8QQ (GB). NICOLL, James, Alan, Ramsay [GB/GB]; The University Court of the University of Glasgow, University Avenue, Glasgow G12 8QQ (GB).

(74) Agent: VALENTINE, Jill, Barbara; SmithKline Beecham, Corporate Intellectual Property, SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB).

(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).

Published

*With international search report.*

*Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: NOVEL METHOD OF PROGNOSING CHRONIC NEURODEGENERATIVE PATHOLOGY FOLLOWING A HEAD INJURY

(57) Abstract

A method of prognosing in a head-injured subject or a subject who may be at risk of sustaining a head injury for the likelihood that a head injury might give rise to a chronic neurodegenerative pathology which could result in neuropsychological, psychiatric or neurological deficits, the method comprising detecting the presence or absence of ApoE isoforms or of DNA encoding ApoE isoforms in the subject.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

# NOVEL METHOD OF PROGNOSING CHRONIC NEURODEGENERATIVE PATHOLOGY FOLLOWING A HEAD INJURY

The present invention relates to methods of prognosing the likelihood of neurodegenerative pathology and dementia in head-injured patients.

5       Accidental or non-accidental head injuries are common events. The precise number of patients suffering a head injury are difficult to calculate exactly since the methods of defining and counting cases varies from country to country. However the relevant figures for the UK serve as a useful guide to the extent of the problem. In the UK some 300 persons per 100,000 of the population are admitted to hospital each  
10       year as a result of head injury. Of these patients 9 per 100,000 will die as a direct result of the severity of their injuries. Outcome surveys in the USA indicate that for every 100 head injury survivors upto 5 remain in a coma, up to 15 are still severely disabled six months after injury, 20 have minor psychiatric or psychological problems and the remaining 60 will make a good recovery. These figures give rise to an  
15       estimated population of some 500, 000 persons in the USA who have a persisting handicap as a result of trauma related head injury. The social and economic cost of dealing with the after effects of such injuries is large<sup>1,2,3,4</sup>.

      The cause of this problem is the brain damage that occurs in up to 30% of patients who are admitted to hospital with a head injury<sup>4</sup>. The damage arises from the  
20       physical effects of the trauma (such as swelling, herniation, haemorrhage, global or focal damage or compromise of the vascular supply, contusion, cranial and peripheral nerve damage, axonal injury and embolism<sup>3,4,5,6</sup>) and also from the neurochemical consequences of the ischaemia which invariably accompanies physical brain damage<sup>3,4,5,6</sup>. Such injuries and subsequent damage are often widespread and can  
25       involve regions of the spinal cord, cranial and peripheral nerves in addition to the brain<sup>1,3,4</sup>.

      In addition the brain damage caused by head injury also produces the risk of subsequent psychiatric and neurologic complications including epilepsy and chronic neuro-degenerative states (eg dementia pugilistica or punch drunk  
30       syndrome)<sup>3,4,5,6,7,8,9,10,11</sup>.

      The extent of brain damage caused by a head injury can vary markedly from patient to patient. Thus, the likelihood and degree of sustaining pathological brain damage in the immediate aftermath of the trauma and the risk of subsequent chronic neurodegeneration leading to epilepsy or a dementing condition vary also.

35       The pathophysiology of head injury has been investigated in an effort to determine the molecular mechanisms which enable the acute triggering event of a head injury to be transformed into a chronic neurodegenerative pathological process<sup>12,13,14,15</sup>.

Head-injured patients show increased levels of  $\beta$  amyloid precursor protein immunoreactivity<sup>14</sup> and some 30% of head injured patients have evidence of  $\beta$  amyloid protein deposition<sup>15</sup>. This deposition can occur within days of a single head injury. The eventual consequence of substantial numbers of  $\beta$  amyloid deposits is the emergence of a clinical syndrome of cognitive decline and increasing dementia<sup>3,8</sup>. Such deposits have been shown to be present in a number of dementing syndromes and these include Alzheimer's disease, cortical Lewy body disease, Parkinson's disease and the Alzheimer-type disease in patients with Down's syndrome<sup>3</sup>. In addition  $\beta$  amyloid deposits are present in the brains of patients with vascular and cerebrovascular disease and these latter conditions can predispose or contribute to the above diseases<sup>3</sup>.

Recently, the apolipoprotein E (ApoE) genotype has been shown to be an important determinant in the etiology of AD<sup>16-23</sup> with the presence and number of E4 alleles being associated with increased risk and earlier ages of onset of disease in both familial cases linked to chromosome 19 and sporadic cases. The presence of E2 alleles has been claimed to decrease the risk (be 'protective') of late onset Alzheimer disease<sup>18,19,24</sup>. This inference is based on the increased frequency of ApoE4 alleles in patients known to have Alzheimer's disease and the later age at onset of disease in patients with the ApoE2/3 genotype compared to the ApoE4/4 genotype<sup>24,25</sup>.

Such general 'protective' effects of the E2 allele have been reported previously in the general population with respect to heart disease<sup>26,27</sup>.

The exact role of ApoE in the pathology of Alzheimer-type disease is uncertain. ApoE is co-localised with  $\beta$  amyloid within plaques in the central nervous system (CNS)<sup>34</sup> and has been shown to bind to  $\beta$  amyloid in vitro<sup>35,36,37</sup> and to tau proteins<sup>28</sup>. This has led to the hypothesis that ApoE/tau interactions are critical in the pathophysiology of tangle formation and thus central to the process of Alzheimer-type diseases<sup>28</sup>. However, neither parkinson dementia complex of Guam nor aged Down's syndrome patients show increased levels of ApoE4 alleles despite the presence of large numbers of tangles in the CNS<sup>29,30</sup>. As such the role of ApoE in the pathology of Alzheimer type dementia remains obscure.

The exact relationship of various environmental factors like head injury to subsequent degenerative conditions like Alzheimer's disease is uncertain. Although epidemiological studies provide some evidence for a link<sup>9</sup> the reason for the susceptibility to a chronic degenerative condition following head injury in some patients<sup>8,9,10,11,15</sup> is unknown at present.

Methods of diagnosing or prognosing Alzheimer's disease have been described (WO 94/09155) based upon detecting (directly or indirectly) the presence or absence of an apolipoprotein E type 4 (ApoE4) isoform in the subject. The ApoE alleles E2, E3 and E4 are described in the literature<sup>31,32</sup>.

It has now been found that the frequency of ApoE4 alleles in those individuals with  $\beta$  amyloid deposition following head injury is of the same high order as that seen in Alzheimer's disease, while in those head injured individuals without  $\beta$  amyloid deposition, the ApoE4 allele frequency is similar to that in non-Alzheimer's disease controls.

This evidence provides the first explanation for the susceptibility of some patients to a chronic neurodegenerative pathological process following the types of brain damage (eg axonal shearing, swelling, herniation, hemorrhage and ischaemia) caused by a head injury.

The present invention therefore provides a method of prognosing in a head-injured subject or a subject who may be at risk of sustaining a head injury for the likelihood that a head injury might give rise to a chronic neurodegenerative pathology which could result in neuropsychological, psychiatric or neurological deficits, the method comprising detecting the presence or absence of ApoE isoforms or of DNA encoding ApoE isoforms in the subject.

The step of detecting the presence or absence of ApoE isoforms or of DNA encoding such isoforms may be carried out either directly or indirectly by any suitable means, such as by techniques well known in the art, and is preferably carried out *ex vivo* (eg by means of the method described<sup>33,38</sup>). All generally involve the step of collecting a sample of biological material containing either DNA or ApoE from the subject, and then detecting which isoforms the subject possesses from that sample. For example, the detecting step may be carried out by collecting an ApoE sample from the subject (for example, from cerebrospinal fluid, or any other fluid or tissue containing ApoE), and then determining the presence or absence of an ApoE isoform in the ApoE sample (eg, by isoelectric focusing or immunoassay). In the alternative, the detecting step may be carried out by collecting a biological sample containing DNA from the subject, and then determining the presence or absence of DNA encoding an ApoE isoform in the biological sample. Any biological sample which contains the DNA of that subject may be employed, including tissue samples and blood samples, with blood cells being a particularly convenient source. Determining the presence or absence of DNA encoding an ApoE isoform may be carried out with an oligonucleotide probe labelled with a suitable detectable group, or by means of an amplification reaction such as a polymerase chain reaction or ligase chain reaction (the product of which amplification reaction may then be detected with a labelled oligonucleotide probe). Further, the detecting step may include the step of detecting whether the subject is heterozygous or homozygous for the gene encoding an ApoE isoform. Numerous different oligonucleotide probe assay formats are known which may be employed to carry out the present invention. Suitable examples

of techniques and strategies for detecting the ApoE isoforms and encoding DNA are described in WO 94/09155.

It will be readily appreciated that the detecting steps may be carried out directly or indirectly. Thus, for example, any of the techniques described above for detecting ApoE2 may instead be used to detect ApoE3 and ApoE4. If either ApoE4 or ApoE3 is also detected in the subject, then it is determined that the subject is not homozygous for ApoE2; and if both ApoE4 and ApoE3 are detected in the subject, then it is determined that the subject is neither homozygous nor heterozygous for ApoE2.

The present invention has utility in enabling improvements in the clinical prognosis of patients who have suffered a degree of brain damage following a head injury.

In addition the invention has utility in allowing definition of the degree of risk in individuals who may be at risk of sustaining a head injury through social or professional activities (eg amateur and professional boxers, divers and other sportsmen such as rugby players, mountain climbers, judo players etc) or through elective medical procedures known to be associated with increased risk of brain damage (eg cardiac bypass operations, carotid endarterectomy, brain surgery etc).

The method of the invention may thus be used to determine the degree of risk in participating in sporting events or clinical procedures. Such prognostications will have considerable utility in the design, planning and implementation of clinical care for patients in the event of a head injury and in the appropriate therapeutic intervention or the degree of hospital/social intervention or support required by a patient deemed to be at greater risk of a neurodegenerative disorder or in the design and analysis of clinical trials to determine the efficacy of therapeutic agents in the treatment of the types of brain damage which occur following head injury.

## EXAMPLE

### 30 Method

Individuals surviving for less than two weeks following a severe head injury were selected from the Glasgow head injury database<sup>4</sup>. Most of the injuries were due to road traffic accidents or falls. Immunostaining for  $\beta$ -amyloid protein ( $\beta$ -AP) and Apolipoprotein E (ApoE) genotyping<sup>38</sup> were performed by standard methods.

35

### Data

Deposits of  $\beta$ -amyloid protein resembling diffuse plaques were present in the cerebral cortex in 23 out of 90 (26%) individuals (Table 1). The ApoE-E4 allele frequency in those individuals with deposition of  $\beta$ -AP was 0.52 (Table 2a)

compared with 0.16 for those individuals without  $\beta$ -AP deposition (chi square 23.013: 1df,  $p < 0.00001$ ). This is similar to the previously published ApoE-E4 frequencies in individuals with Alzheimer's disease and age-matched control, respectively. Age stratification of the data indicates that the relationship between ApoE-E4 and  $\beta$ -AP deposition holds for those head-injured patients under 60 years of age (Table 2b). The proportion of head-injured individuals with  $\beta$ -AP deposition for each ApoE genotype is shown in Table 3. The proportion of head-injured individuals with  $\beta$ -AP deposition increased with the number of ApoE-E4 alleles (Table 4) from 10% for those without an E4 allele, to 35% for those with one E4 allele, to 100% (6 out of 6) for the relatively rare E4 homozygote. Within the group of patients with  $\beta$ -AP deposits, when the plaque density was assessed semi-quantitatively (sparse, moderate, frequent) it was found to be related to ApoE-E4 gene dose (Table 5).

**Table 1** Descriptive statistics for head-injured individuals with ( $\beta$ -AP+) and without ( $\beta$ -AP-)  $\beta$ -AP deposition

	$\beta$ -AP+	$\beta$ -AP-
Number	23	67
Age (years)		
<i>mean <math>\pm</math> SD</i>	52 $\pm$ 19	28 $\pm$ 18
<i>range</i>	14-75	0.15-79
Survival following head injury (days)		
<i>mean <math>\pm</math> SD</i>	3.3 $\pm$ 4	2.9 $\pm$ 3
<i>range</i>	<1-13	<1-13

**Table 2** ApoE allele frequencies in head-injured individuals with  $\beta$ -AP deposition ( $\beta$ -AP+) and without ( $\beta$ -AP-)

**a. All head-injured patients**

ApoE allele	$\beta$ -AP+	$\beta$ -AP-
E2	1/46 (0.02)	14/134 (0.1)
E3	21/46 (0.46)	98/134 (0.73)
*E4	24/46 (0.52)	22/134 (0.16)

\* $\chi^2 = 23.013$ , 1df,  $p < 0.00001$

**b. Head-injured patients under 60 years of age**

ApoE allele	$\beta$ -AP+	$\beta$ -AP-
**E4	14/28 (0.5)	22/126 (0.16)

\*\* $\chi^2 = 13.542$ , 1df,  $p < 0.001$

**Table 3** Proportion of individuals with deposition of  $\beta$ -AP ( $\beta$ -AP+) according to ApoE genotype

ApoE genotype	Proportion of individuals $\beta$ -AP+	Percentage
2/2	0/2	0%
2/3	0/7	0%
3/3	5/41	12%
2/4	1/4	25%
3/4	11/30	37%
4/4	6/6	100%

5

**Table 4** Proportion of individuals with deposition of  $\beta$ -AP ( $\beta$ -AP+) according to the ApoE-E4 gene dose.

ApoE-E4 gene dose	Proportion of $\beta$ -AP+ individuals	Percentage
0	5/50	10%
1	12/34	35%
2	6/6	100%

$\chi^2$  for trend =22.85, 1df,  $p < 0.001$

10

**Table 5**  $\beta$ -AP plaque numbers according to the ApoE-E4 gene dose.

ApoE-E4 gene dose	Proportion of head-injured patients with 'frequent' $\beta$ -AP plaques	Percentage
0	0/5	0%
1	4/12	33%
2	4/6	66%

$\chi^2$  for trend  $p = 0.02$

## 15 References

1. D W Anderson, R L McLaurin. Report on the national head and spinal cord injury survey conducted for the National Institute of neurological and Communicative Disorder & Stroke. Jour of Neurosurg, 1980, 53: Suppl. S1-S43.

20



2. W F Caveness. Incidence of craniocerebral trauma in the United States in 1976 with trend from 1970 to 1975. In: Thompson R . Green J R (ed). Advances in neurology, Vol. 22, Complications of nervoussystem trauma. Raven Press, New York, 1979, p1.
- 5 3. Roberts G W, Leigh P N and Weinberger D. Neuropsychiatric Disorders. Gower Medical press. London 1993..
- 10 4. JH Adams. Head injury. In: JH Adams & LW Duchen (Eds.), Greenfield Neuropathology, 5th edition 1992. Edward Arnold, London, Melbourne, Auckland. p106-152.
- 15 5. JH Adams, D. Doyle, I Ford, TA Genarelli, DI Graham & DR McLellan. Diffuse axonal injury in head injury: definitions, diagnosis and grading. Histopathology 1989, 15: 49-59.
6. Anon editorial. Head trauma victims in the UK: undeservedly underserved. Lancet 1990, 335 886-887.
- 20 7. JAN Corsellis, CJ Bruton & D Freeman-Browne. The aftermath of boxing. Psychol Med 1973, 3: 270-273.
8. WA Lishman. Senile dementias, presenile dementias and pseudodementias. In: Organic Psychiatry, 2nd edition, Blackwell Scientific, London, Oxford 1987.
- 25 9. JA Mortimer, CM Van Duijn, & V Chandra. Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. Int. J Epidemiol 1991, 20: S28.
- 30 10. AJ Roberts. Brain Damage in Boxers. Pitman, London (1969).
11. R Rudelli, JO Strom & PT Welch. Post-traumatic premature Alzheimer's disease: neuropathologic findings and pathogenic considerations. Arch Neurol, 1982, 39: 570-575.
- 35 12. GW Roberts. Immunocytochemistry of neurofibrillary tangles in dementia pugilistica and Alzheimer's disease: evidence for common genesis. Lancet, 1988, 2(8626-8627): 1456-1458.

13. GW Roberts, D Allsop & CJ Bruton. The occult aftermath of boxing. *J Neurol Neurosurg Psychiatry*, 1990a, 53: 373-378.
- 5 14. SM Gentleman, DI Graham and GW Roberts. Molecular pathology of head trauma: altered BAPP metabolism and the etiology of Alzheimer's disease. *Progress in Brain Research*, 1993 96: 237-246.
- 10 15. GW Roberts, SM Gentleman, A Lynch, L Murray, M Landon & DI Graham.  $\beta$ -amyloid protein deposition in the brain following severe head injury: implications for the pathogenesis of Alzheimer's disease. *Journal of Neurology, Neurosurgery and Psychiatry* 1994; 57: 419-425.
- 15 16. A M Saunders, W J Strittmatter, D Schmechel, P H St George-Hyslop, M A Pericak-Vance, S H Joo, B L Rosi, J F Gusella, D R Crapper-MacLachlan, M J Alberts, C Hulette, B Crain, D Goldgaber & A D Roses. Association of Apolipoprotein E allele E4 with late-onset familial and sporadic Alzheimer's disease. *Neurology* 1993; 43: 1467-1472.
- 20 17. E H Corder, A M Saunders, W J Strittmatter, D E Schmechel, P C Gaskell, G W Small, A D Roses, J L Haines, M A Pericak-Vance. Gene dose of Apolipoprotein E Type 4 Allele and the risk of Alzheimer's Disease in late onset families. *Science*, 1993; 261: 921.
- 25 18. E H Corder, A M Saunders, N J Riech, W J Strittmatter, D E Schmechel, P C Gaskell Jr., J B Rimmer, P A Locke, P M Connelly, K E Schmader, G W Small, A D Roses, J L Haines & M A Pericak-Vance. Protective effect of Apolipoprotein E2 allele decreases risk of late-onset Alzheimer's disease. *Nature Genetics* 1994; 7: 1-7.
- 30 19. C Talbot, C Lendon, N Craddock, S Shears, J C Morris, A Goate. Protection against Alzheimer's disease with ApoE E2. *The Lancet* 1994; 343: 1432-1433.
- 35 20. A M Saunders, K Schmader, C S Breitner, M D Benson, W T Brown, L Goldfarb, D Goldgaber, M G Manwaring, M H Szymanski, M McCown, K C Dole, D E Schmechel, W J Strittmatter, M A Pericak-Vance, A D Roses. Apolipoprotein E E4 allele distribution in late-onset Alzheimer's disease and in other amyloid-forming diseases. *Neurology* 1993; 342: 710-711.

21. J Poirier, J Davignon, D Bouthillier, S Kogan, P Bertrand, S Gauthier. Apolipoprotein E polymorphism and Alzheimer's disease. *The Lancet* 1993; 342: 697-699.
- 5 22. D S Borgaonkar, L C Schmidt, S E Martin, M D Kanzer, L Edelson, J Growdon, L A Farrer. Linkage of late-onset Alzheimer's disease with Apolipoprotein E4 on chromosome 19. *The Lancet*, 1993: 342: 625.
- 10 23. R Mayeux, Y Stern, R Ottman, T K Tatemichi, M-X Tang, G Maestre, B S Coleen Ngai, B Tyoko & H Ginsberg. The Apolipoprotein E4 allele in patients with Alzheimer's disease. *American Neurological Association* 1993; 34: 752-754.
- 15 24. Allen D Roses, Warren J Strittmatter, Margaret A Pericak-Vance, Elizabeth H Corder, Ann M Saunders, Donald E Schmechel. *et al* *Lancet*. Clinical application of apolipoprotein E genotyping to Alzheimer's disease. 1994; 343: 1564-1565.
- 20 25. Houlden H, Collinge J, Kennedy A, Newman S, Rossor M, Lannfelt L, Lilius L, Winblad B, Crook R, Duff K and Hardy J. ApoE genotype and Alzheimer's disease. *Lancet* 1993, 342, 737-738.
- 25 26. K Kervinen, M J Sovalainen, J Salokannel, A Hynninen, J Heikkinen, C Ehnholm, M J Koistinen, Y A Kesaniemi. Apolipoprotein E and B polymorphisms - longevity factors assessed in nonagenarians. *Atherosclerosis* 1994; 105: 89-95.
- 30 27. F Schachter, L Faure-Delanef, F Guenot, H Rouger, P Froguel, L Lesueur-Ginot & D Cohen. Genetic associations with human longevity at the ApoE and ACE loci. *Nature Genetics* 1994; 6: 29-32.
- 35 28. W J Strittmatter, K H Weisgraber, M Goedert, A M Saunders, D Huang, E H Corder, L-M Dong, R Jakes, M J Alberts, J R Gilbert, Seol-Heui Han, C Hulette, G Einstein, D E Schmechel, M A Pericak-Vance & A D Roses. Hypothesis: Microtubule instability and paired helical filament formation in the Alzheimer Disease brain are related to Apolipoprotein E genotype. *Experimental Neurology* 1994; 125: 163-171.

29. S C Waring, P C O'Brien, L T Kurland, S N Thibodeau, M-S Tsai, R C Petersen, C E Esteban-Santilan. Apolipoprotein E allele in Chamorros with amyotrophic lateral sclerosis/parkinsonism-dementia complex. *The Lancet*, 1994; 343; 611.
- 5
30. J Hardy, R Crook, R Perry, R Raghavan & G W Roberts. ApoE genotype and Down's syndrome. *The Lancet* 1994; 343: 979-980.
- 10
31. H K Das, J McPherson, G A Bruns, S K Karathanasis, J L Breslow. Isolation, characterization and mapping to chromosome 19 of the human apolipoprotein E gene. *J Biol. Chem.* 1985; 260: 6240-6247.
- 15
32. J M Taylor, S Lauer, N Elshourbagy, C Reardon, E Taxman, D Walker, D Chang & Y K Paik. Structure and evolution of human Apolipoprotein genes: Identification of regulatory elements of the human Apolipoprotein E gene. *Ciba Found. Symp.* 1987; 130: 70-86.
- 20
33. E H Hixson and D T Vernier. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. *Journal of Lipid Research* (1990) 31: 545-548.
- 25
34. Y Namba, Tomonaga M, Kawasaki H, Otomo E & Ikeda K. Apolipoprotein E immunoreactivity in cerebral deposits and neurofibrillary tangles in Alzheimer's disease. *Brain Res.* 541, 163-166 (1991).
- 30
35. W J Strittmatter *et al.* Apolipoprotein E - High avidity binding to  $\beta$ -amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. *Proc. Natn. Acad. Sci. U.S.A.* 90, 1977-1981(1993).
- 35
36. W J Strittmatter *et al.* Binding of human apolipoprotein E to synthetic amyloid  $\beta$ -peptide. Isoform specific effects and implications for late onset Alzheimer's disease. *Proc. Natn. Acad. Sci. U.S.A.* 90, 8098-8102 (1993).
37. J Ma, A Yee, B Brewer, S Das & H Potter. Amyloid-associated proteins  $\alpha$ 1 antichymotrypsin and apolipoprotein E promote assembly of Alzheimer  $\beta$ -protein into filaments. *Nature* 372, 92-94 (1994).
38. P R Wenham, W H Price & G Blundell. Apolipoprotein E genotyping by one-stage PCR. *Lancet* 337, 1158-1159 (1991).

**CLAIMS**

1. A method of prognosing in a head-injured subject or a subject who may be at risk of sustaining a head injury for the likelihood that a head injury might give rise to a chronic neurodegenerative pathology which could result in neuropsychological, psychiatric or neurological deficits, the method comprising detecting the presence or absence of ApoE isoforms or of DNA encoding ApoE isoforms in the subject.
2. A method according to claim 1 wherein the step of detecting the presence or absence of ApoE isoforms or of DNA encoding such isoforms is carried out *ex vivo*.
3. A method according to claim 2 wherein said detection step involves collecting a sample of biological material containing DNA from the subject.
4. A method according to claim 3, wherein the biological sample is blood.
5. A method according to claim 2 wherein said detection step involves collecting a sample of biological material containing ApoE from the subject.
6. A method according to claim 5, wherein the biological sample is cerebrospinal fluid.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT, EP 95/02827

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 G01N33/68 G01N33/92

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DISSERTATION ABSTRACTS INTERNATIONAL B, vol. 54, no. 4, 1 October 1993 WASHINGTON DC USA, page 1827 D.M. VANDERPUTTEN 'Identification and characterization of apolipoprotein E in human neurodegeneration.' see the whole document ---	1-6
A	WO,A,94 09155 (DUKE UNIVERSITY) 28 April 1994 cited in the application see the whole document ---	1-6
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*A\* document member of the same patent family

Date of the actual completion of the international search

24 November 1995

Date of mailing of the international search report

01.12.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Van Bohemen, C

# INTERNATIONAL SEARCH REPORT

International Application No

PCT, LP 95/02827

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY ,  vol. 57, 1 January 1994 LONDON UK,  pages 419-425,  G.W. ROBERTS ET AL. 'beta-Amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease.'  see the whole document  ---</p>	1-6
T	<p>NATURE MEDICINE,  vol. 1, no. 2, 1995 WASHINGTON DC USA,  pages 135-137,  J.A.R. NICOLL ET AL ET AL 'Apolipoprotein E epsilon-4 allele is associated with deposition of amyloid beta-protein following head injury.'  see page 135, column 1, line 7 - line 10  -----</p>	1-6

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/EP 95/02827

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9409155	28-04-94	AU-B- 5350094	09-05-94
		CA-A- 2142300	28-04-94
		CN-A- 1092525	21-09-94
		EP-A- 0625212	23-11-94
		FI-A- 951701	10-04-95
		JP-T- 7502418	16-03-95
		NO-A- 951383	07-04-95
<hr/>			